ADC Therapeutics
ADCT
83 hedge funds and large institutions have $112M invested in ADC Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 10 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 16
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
8% more funds holding
Funds holding: 77 → 83 (+6)
1.67% more ownership
Funds ownership: 56.76% → 58.43% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
35% less capital invested
Capital invested by funds: $173M → $112M (-$60.5M)
50% less call options, than puts
Call options by funds: $51K | Put options by funds: $102K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$5.06M |
| 2 |
O
OrbiMed
New York
|
+$3.75M |
| 3 |
Morgan Stanley
New York
|
+$2.4M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$2.21M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$1.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$5.65M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$3.66M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$3.16M |
| 4 |
GGH
GCM Grosvenor Holdings
Chicago,
Illinois
|
-$1.29M |
| 5 |
D.E. Shaw & Co
New York
|
-$895K |
ADCT Hedge Fund Activity: Q4 2024 in Review
83 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q4 2024, worth a combined $112M — down 35% from $173M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ADCT positions and 10 closed out — a net gain of 6 holders — while 33 added to existing stakes and 16 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $5.06M. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $5.65M sold.
- 83 institutional investors held ADC Therapeutics (ADCT) as of Q4 2024, up from 77 in Q3 2024.
- Funds reported $112M of ADC Therapeutics stock for Q4 2024, down 35% quarter-over-quarter.
- 16 funds opened new ADC Therapeutics positions in Q4 2024 and 10 closed out, a net change of +6 holders.
- The largest ADC Therapeutics buyer in Q4 2024 was Woodline Partners, an estimated $5.06M added.
- The largest ADC Therapeutics seller in Q4 2024 was Silverarc Capital Management, an estimated $5.65M sold.
Based on aggregated 13F filings for Q4 2024.